BioSpace News Archive

icotec ag announces that the KONG®-TL and the KONG®-C vertebral body replacement systems with the unique Titaniumcoating (Ti-iT®) receive FDA 510(k) clearance in the United States and CE approval in Europe .

Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15,384,614 shares (including 2,006,688 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares) of its common stock, par value $0.001 per share.

Spectroscopy®, a multimedia platform that promotes the use of spectroscopic instrumentation in applied research, environmental testing, quality control, and the life sciences, and the Society for Applied Spectroscopy (SAS), are pleased to announce a joint virtual conference, “Molecular Spectroscopy in Practice,” taking place July 22–23.

A June 4, 2020 study published in Plos Pathogens reveals that women taking antibiotics for BV may be able to improve treatment outcomes if vaginal probiotics with Lactobacillus are taken in conjunction.

Today, the U.S. Food and Drug Administration approved Crysvita (burosumab-twza) injection to treat patients age two and older with tumor-induced osteomalacia (TIO), a rare disease that is characterized by the development of tumors that cause weakened and softened bones. The tumors associated with TIO release a peptide hormone-like

Epizyme, Inc. (Nasdaq:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for TAZVERIK™

Scientists have further decoded how mammalian brains perceive odors and distinguish one smell from thousands of others.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, announced the election of Peter Svennilson, Managing Partner of The Column Group, to its Board of Directors.

NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced the publication of four abstracts on developmental therapeutics for immunotherapy, molecularly targeted agents and tumor biology during the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.

Neauvia North America announces the release of NPURE, an FDA Class I medical device in the U.S. Market to address the need for additional disinfection methods in a COVID-19 environment. [18-June-2020] RALEIGH, N.C. , June 18, 2020 /PRNewswire/ -- Neauvia North America has announced that NPURE is a Food and Drug Administration (FDA) Class I device that offers the wel